Additional file 20: of HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer
- Andrew Teschendorff (95936)
- Shih-Han Lee (184672)
- Allison Jones (184670)
- Heidi Fiegl (152035)
- Marie Kalwa (3563498)
- Wolfgang Wagner (47115)
- Kantaraja Chindera (802998)
- Iona Evans (3429239)
- Louis Dubeau (193226)
- Arturo Orjalo (3563501)
- Hugo Horlings (40754)
- Lukas Niederreiter (3563504)
- Arthur Kaser (280904)
- Winnie Yang (453615)
- Ellen Goode (3445394)
- Brooke Fridley (3528998)
- Richard Jenner (3563495)
- Els Berns (3525377)
- Elisabeth Wik (106776)
- Helga Salvesen (106800)
- G. Wisman (3563516)
- Ate van der Zee (3563513)
- Ben Davidson (49188)
- Claes Trope (3563507)
- Sandrina Lambrechts (205147)
- Ignace Vergote (205151)
- Hilary Calvert (3563510)
- Ian Jacobs (1986847)
- Martin Widschwendter (184711)
Publication date
October 2015
DOIAbstract
Kaplan-Meier survival estimates for patients whose tumours expressed HOTAIR (a, c) and whose tumours did not express HOTAIR (b, d) in the INNSBRUCK (a, b) and GRONINGEN sets (c, d). Survival analysis was performed according to the type of chemotherapy patients received: carboplatin monotherapy (Carbo-Mono), carboplatin-paclitaxel (Carbo-Pacli), carboplatin-cyclophosphamide (Carbo-Cyclo) or cisplatin-based chemotherapy (Cisplat). Hazard ratios (HR) and P values were calculated comparing cisplatin- with carboplatin-based chemotherapy regimens. (PDF 281 kb
Add to ORKG